Alignment Healthcare LLC (ALHC)

Joseph S. Konowiecki, EVP of Corporate Affairs and Director at Alignment Healthcare, Inc. (NASDAQ:ALHC), sold 23,511 shares on September 17, 2026. This sale, at a weighted-average price of $8.61 per share, was executed solely to cover tax withholding obligations related to vested restricted stock units, not as a discretionary trade. Following the transaction, Konowiecki retains direct beneficial ownership of 1,080,305 shares.

An insider at Alignment Healthcare recently sold shares valued at $356,200, as detailed in a recent SEC filing. This transaction follows other significant insider share sales at the company in recent weeks, indicating active insider trading. Alignment Healthcare, Inc. (ALHC) operates Medicare Advantage Plans and reported its Q2 2026 earnings with revenue increases and guidance for Q3 and full-year.

Alignment Healthcare (ALHC) has experienced a significant 57% slide in its share price this year, prompting investors to scrutinize its market valuation against its earnings potential. Despite legislative changes potentially impacting Medicare Advantage margins, the company's P/E ratio of 44.4x, though higher than sector and peer averages, is considered "about right" by a fair-multiple model, suggesting the market has already factored in these risks. The article explores whether the current stock price aligns with its current and future earnings, highlighting an analyst narrative that suggests it could be significantly undervalued.

Stocks for Astrana Health, Clover Health, Alignment Healthcare, and Novavax traded down after bipartisan lawmakers introduced the Protecting Approved Care Act. This legislation aims to reform prior authorization and payment rules in Medicare Advantage plans, potentially impacting health insurers' operating margins by limiting their ability to retroactively deny reimbursements. Alignment Healthcare experienced a significant 12.6% drop, with its shares trading 58% below its 52-week high.

Alignment Healthcare (ALHC) shares fell 22% after executives at a Baird conference refused to discuss next year's Medicare Advantage star ratings and acknowledged higher-than-expected hospital costs. CEO John Kao cited CMS sensitivity for the silence on star ratings, while CFO Jim Head highlighted ongoing issues with institutional spending. The company attributed recent challenges to a system overhaul, though retail investor sentiment for both ALHC and Clover Health (CLOV) has risen.